InnoCare receives China approval for Minjuvi® DLBCL treatment

InnoCare Pharma Limited (HKEX:9969) announced that the National Medical Products Administration (NMPA) in China has approved Minjuvi® (tafasitamab) in combination with lenalidomide, followed by Minjuvi monotherapy, for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). This approval marks the first CD19 antibody treatment approved for relapsed or refractory DLBCL in China. DLBCL accounts for 45.8% of all NHL cases in China. Minjuvi has already been approved for eligible DLBCL patients in Hong Kong, Macau, and Taiwan. Tafasitamab received accelerated approval by the U.S. FDA and conditional approval by the European Medicines Agency (EMA) for similar DLBCL treatments.